Zolephos 5mg/100ml Infusion

Zolephos is contraindicated in patients with hypersensitivity to zoledronic acid or other bisphosphonates, severe renal impairment, or hypocalcemia. Prior to administration, calcium levels should be corrected, and renal function monitored due to potential nephrotoxicity. Common adverse effects include acute phase reactions such as fever, myalgia, and flu-like symptoms, which are generally transient.

Adequate hydration before and after infusion is recommended to minimize renal risk. Zolephos should be used under strict medical supervision with appropriate monitoring to ensure efficacy and safety. This formulation provides a convenient and effective option for managing bone disease associated with malignancy and metabolic bone disorders.